Product Description
ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04840784)
Mechanisms of Action: FLT3 Inhibitor, CDK4 Inhibitor, CDK6 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shengke Pharmaceuticals
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Myeloid Leukemia|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05758610 |
ETH-155008- 101 | P1 |
Recruiting |
Hodgkin Lymphoma|Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin |
2025-12-01 |
54% |
2024-05-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
CTR20222130 |
CTR20222130 | P1 |
Recruiting |
Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|